CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 320 enrolled
Drug / intervention
tDCS Parametersdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07452835
NCT07452835N/ACompleted

Transcranial Direct Current Stimulation (tDCS) in Different Psychiatric Disorders

Menoufia University·interventional·Posted Mar 5, 2026·Updated Mar 6, 2026

In Brief

A clinical study evaluating tDCS Parameters for Major Depressive Disorder (MDD) and 4 related conditions. Completed, enrolled 320 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in reducing core symptoms of different psychiatric disorders using validated clinical scales. * To assess response and remission rates. * To evaluate the durability of treatment effects over follow-up. * To examine effects on cognition, daily functioning, and quality of life. * To monitor tolerability and adverse events.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesEgypt
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedMar 5, 2026
Enrollment StartJan 1, 2024
Primary CompletionJun 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 4 months ago

Interventions

tDCS Parametersdevice

Preparation: * Clean scalp with alcohol to reduce impedance. * Apply conductive gel and position electrodes using the 10-20 EEG system. * Use rubber electrodes (5×7 cm) for anodal/cathodal placement. Stimulation: Ramp-up current over 30 sec to avoid discomfort. Monitor for adverse effects (tingling, itching, headache ). Post-Stimulation Assessment: * Evaluate symptom changes using standardized scales (e.g., HAM-D for depression, Y-BOCS for OCD). * Repeat sessions 3-5 times per week.. Safety and Monitoring Adverse Effects: Mild skin irritation, headache (rarely seizures-screen high-risk patients(. Contraindications: Metallic implants, scalp lesions, epilepsy history. Conclusion tDCS is a promising neuromodulatory tool for psychiatric disorders, with varying protocols based on disorder-specific neural targets.